Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

• Hauptverfasser: Qiao Liu (Verfasst von), Zhen Zhou (Verfasst von), Xia Luo (Verfasst von), Lidan Yi (Verfasst von), Liubao Peng (Verfasst von), Xiaomin Wan (Verfasst von), Chongqing Tan (Verfasst von), Xiaohui Zeng (Verfasst von)
• Format: Buch
• Veröffentlicht: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...